Study guide

8.1 Canadian Federal Legislation: Food and Drugs Act & CDSA

PEBC Pharmacy Technician Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Introduction: PEBC Technician Qualifying Exam Part I Overview

0.1 Exam Facts, 2026 Blueprint & Test-Taking Strategy

2 Chapter 1: Prescription Intake, Adjudication & Processing

1.1 Prescription Legal Validity, Essential Elements & Order Intake 1.2 Patient Profile Setup, Drug Insurance & Third-Party Adjudication 1.3 Order Clarification, Refill Authorizations & Prescription Transfers

3 Chapter 2: Pharmaceutical Calculations for Pharmacy Practice

2.1 Metric Conversions, Ratio Strengths & Percentage Concentrations 2.2 Dosing Regimens, Days Supply & Pediatric/Geriatric Calculations 2.3 Alligation Alternate & Concentration Adjustments 2.4 IV Flow Rates, Infusion Times & Electrolyte Solutions

4 Chapter 3: Non-Sterile Compounding & NAPRA Standards

3.1 NAPRA Non-Sterile Standards, Facilities & Equipment Requirements 3.2 Master Formulation Records, Compounding Procedures & Beyond-Use Dates 3.3 Hazardous Non-Sterile Handling & Quality Assurance

5 Chapter 4: Sterile Compounding & Aseptic Technique

4.1 Cleanroom Engineering Controls, ISO Classifications & Airflow Workstations 4.2 Aseptic Technique, Hand Hygiene & Garbing Protocols 4.3 Parenteral Admixtures, Reconstitution & Sterile Beyond-Use Dates

6 Chapter 5: Product Release, Verification & Dispensing Systems

5.1 Technical Verification & Independent Double Checks 5.2 Final Product Inspection, Packaging & Auxiliary Labelling 5.3 Automated Dispensing Cabinets, Unit-Dose Systems & Technology 5.4 Patient Handover, Identity Verification & Technical Device Demonstrations

7 Chapter 6: Inventory Control, Cold Chain & Drug Distribution

6.1 Inventory Management, Ordering & Stock Rotation (FIFO) 6.2 Cold Chain Management, Temperature Monitoring & Excursion Protocols 6.3 Drug Recalls, Quarantine Protocols & Safe Disposal

8 Chapter 7: Patient Care & Clinical Support for Pharmacy Technicians

7.1 Patient Data Collection & Best Possible Medication History (BPMH) 7.2 Screening for Drug Therapy Problems & Pharmacist Referral Triggers 7.3 Compliance Packaging, Adherence Aids & Patient Support 7.4 Physical Measurements, Point-of-Care Testing & Supporting Medication Administration

9 Chapter 8: Canadian Pharmacy Legislation & Regulatory Framework

8.1 Canadian Federal Legislation: Food and Drugs Act & CDSA 8.2 Controlled Substances: The Controlled Substances Regulations, Narcotics, Controlled Drugs, Targeted Substances & Cannabis 8.3 Provincial Colleges of Pharmacy, Technician Scope of Practice & Privacy Laws

10 Chapter 9: Patient Safety, Continuous Quality Improvement & Ethics

9.1 Medication Incident Reporting, Root Cause Analysis & Continuous Quality Improvement 9.2 Error Prevention Strategies, High-Alert Medications & LASA Safeguards 9.3 Code of Ethics, Confidentiality & Professional Boundaries 9.4 Equity, Diversity, Inclusion & Cultural Safety in Pharmacy Practice

11 Chapter 10: Pharmacology Foundations, Communication & Public Health

10.1 Key Canadian Drug Classes, Common Indications & Canadian Brand/Generic Names 10.2 Evidence-Informed Decision Making & Authoritative Drug Information References 10.3 Interprofessional Collaboration, Effective Communication & Documentation Standards 10.4 Public Health Promotion, Harm Reduction & Community Wellness Programs

8.1 Canadian Federal Legislation: Food and Drugs Act & CDSA

Key Takeaways Explain This Topic AI

The Food and Drugs Act and Food and Drug Regulations set national standards for drug safety, efficacy, quality, manufacturing, packaging and labelling across Canada.

The Prescription Drug List (PDL) replaced the former Schedule F in December 2013 and lists the medicinal ingredients that require a prescription for human or veterinary use.

An 8-digit Drug Identification Number (DIN) shows that a drug product is authorized for sale in Canada; natural health products carry an 8-digit NPN or a DIN-HM.

Section 3 of the Food and Drugs Act bans advertising to the public any product as a treatment, preventative or cure for a Schedule A disease, and prescription drug ads are limited to name, price and quantity.

A pharmacist must send Health Canada a written report of any loss or theft of a controlled substance within 10 days after becoming aware of it; thefts are also reported to police.

Last updated: September 2026

Canadian Federal Legislation: Food and Drugs Act & CDSA

Exam Tip: On the PEBC Qualifying Examination, candidates must thoroughly understand the division between federal and provincial authority. Federal legislation governs the product (safety, efficacy, quality, manufacturing, import/export, and criminal scheduling), whereas provincial legislation governs the practice (licensing of pharmacies, registration of professionals, and operational scopes). Candidates are frequently tested on identifying Health Canada packaging symbols, advertising limits, and strict statutory loss/theft reporting deadlines.

The Canadian Federal Legislative Framework

In Canada, the authority of the federal government over medications and controlled substances is grounded in the constitutional power over criminal law and national trade. The primary federal health department is Health Canada ( Santé Canada ), headed by the federal Minister of Health. Within Health Canada, specialized branches—such as the Health Products and Food Branch (HPFB) and the Office of Controlled Substances (OCS)—oversee the regulatory lifecycle of pharmaceuticals, biological products, medical devices, natural health products, and controlled substances.

Two central federal statutes establish the legal backbone of pharmacy inventory and drug safety across all provinces and territories:

The Food and Drugs Act (FDA) and its subordinate regulations, primarily the Food and Drug Regulations (FDR) and the Natural Health Products Regulations (NHPR) .

The Controlled Drugs and Substances Act (CDSA) and its regulations. Since October 1, 2026 , pharmacy activities with narcotics, controlled drugs and targeted substances are governed by the consolidated Controlled Substances Regulations (CSR) , which replaced the Narcotic Control Regulations (NCR), the Benzodiazepines and Other Targeted Substances Regulations (BOTSR), and Parts G and J of the FDR.

The Food and Drugs Act (FDA) & Food and Drug Regulations (FDR)

The Food and Drugs Act is an act of the Parliament of Canada regarding the production, import, export, transport across provinces, and sale of food, drugs, contraceptive devices, and cosmetics. Its core purpose is to protect the Canadian public against health hazards, fraud, adulteration, and misleading claims in the sale and use of foods, drugs, cosmetics, and medical devices.

The Prescription Drug List (PDL) and the Schedule F Legacy

Historically, prescription-only medications in Canada were listed under Schedule F of the Food and Drug Regulations. In December 2013, Health Canada officially replaced Schedule F with the Prescription Drug List (PDL) .

The PDL is an administrative list maintained by Health Canada under the Food and Drugs Act and incorporated by reference into the Food and Drug Regulations, so it can be updated without amending the regulations.

It contains medicinal ingredients that require a prescription for human or veterinary use when sold in Canada.

The PDL is divided into two separate sections:

Human Use List: Active ingredients intended for administration to humans requiring a prescription (e.g., atorvastatin, amoxicillin, metformin, lisinopril).

Veterinary Use List: Active ingredients intended for administration to animals requiring a veterinary prescription.

Crucial Distinction: Controlled substances, narcotics, and targeted substances are governed separately under the CDSA and are not listed on the PDL.

Drug Identification Numbers (DIN)

Under Section C.01.014 of the Food and Drug Regulations, no manufacturer may sell a drug in dosage form in Canada unless a Drug Identification Number (DIN) has been issued by Health Canada:

A DIN is an 8-digit numerical code assigned to each approved prescription, non-prescription (OTC), or biological drug product.

A DIN shows that Health Canada has authorized the product for sale in Canada. For new drugs, including most generics, that authorization follows a Notice of Compliance (NOC) issued after a review of safety, efficacy and quality data.

Any change in the active ingredient, strength, dosage form, route of administration, or brand name necessitates an application for a distinct, separate DIN.

Natural Health Products (NHPs): NPN and DIN-HM

Regulated under the Natural Health Products Regulations (NHPR) , natural health products include herbal remedies, vitamins, mineral supplements, essential fatty acids, probiotics, traditional medicines (e.g., traditional Chinese medicines), and homeopathic preparations:

Natural Product Number (NPN): An 8-digit numeric code appearing on the front label of natural health products, confirming that Health Canada has evaluated and approved the product for safety, efficacy, and Good Manufacturing Practices (GMP).

Homeopathic Medicine Number (DIN-HM): An 8-digit numeric code specific to homeopathic preparations authorized under the NHPR.

Natural health products must not contain substances listed on the Prescription Drug List (PDL) or schedules of the CDSA.

Packaging and Labelling Requirements under the FDR

Health Canada enforces strict packaging and labelling standards to guarantee that both healthcare professionals and patients can readily identify medications, prepare accurate doses, and handle products safely.

Inner and Outer Label Specifications

The FDR defines an inner label as the label on or affixed to an immediate container (e.g., stock bottle, vial, blister strip), and an outer label as the label on or affixed to the outside packaging (e.g., cardboard carton, box).

  • Mandatory Label Element Inner Container Label Outer Packaging Carton
  • Brand / Proprietary Name Required Required

Proper / Generic Chemical Name Required (immediately adjacent to brand name) Required (immediately adjacent to brand name)

  • Strength & Dosage Form Required (e.g., 20 mg tablet, 50 mg/mL) Required
  • Drug Identification Number (DIN) Required (8-digit code, e.g., DIN 01234567) Required
  • Manufacturer / Distributor Name & Address Required (at least city and country) Required (full legal address)
  • Lot / Batch Number Required (preceded by "Lot", "(L)", or "Batch") Required
  • Expiration Date Required (year and month, e.g., 2027-AL) Required
  • Net Quantity / Contents Required if space permits Required (e.g., 100 Tablets, 500 mL)
  • Storage Conditions Required (e.g., Store at 15°C–30°C; Protect from light) Required
  • Bilingual Labelling French and English required French and English required
  • Federal Warning Symbols and Scheduling Indicators

The front label of a pharmaceutical product must display distinct statutory symbols in the upper left quadrant of the main display panel to communicate its legal status:

Pr Symbol: Indicates a prescription drug listed on the federal Prescription Drug List (PDL).

C Symbol: Indicates a controlled drug (e.g., methylphenidate, lisdexamfetamine, phenobarbital, testosterone). Controlled drugs were in Part G of the FDR until September 30, 2026, and are now in Schedule 2 of the CSR.

N Symbol: Indicates a narcotic (e.g., morphine, oxycodone, codeine, tramadol, nabilone), formerly under the NCR and now in Schedule 1 of the CSR.

T/C Symbol: Indicates a targeted substance (e.g., lorazepam, diazepam, zolpidem). Zopiclone is a prescription drug but not a controlled substance in Canada.

Canadian Advertising Restrictions: Direct-to-Consumer Rules

Direct-to-consumer advertising (DTCA) of prescription drugs in Canada is subject to some of the strictest legal restrictions in the developed world, contrasting sharply with United States practices.

Section 3 Prohibitions (Schedule A Diseases)

Under Section 3 of the Food and Drugs Act , no person shall advertise any food, drug, cosmetic, or device to the general public as a treatment, preventative, or cure for any disease, disorder, or abnormal physical state listed in Schedule A .

Schedule A lists serious conditions such as cancer, diabetes, hypertension, asthma, congestive heart failure, depression, convulsions and sexually transmitted diseases.

The rationale is to prevent vulnerable patients from self-diagnosing or self-medicating potentially fatal conditions without medical supervision.

Permissible Prescription Drug Advertising Categories in Canada

Health Canada's Policy on The Distinction Between Advertising and Other Activities allows only two limited formats for public communication regarding prescription medications:

Reminder Advertisements:

May mention the brand name , price , and quantity of a prescription drug.

Strict Prohibition: Must NOT mention the disease state, therapeutic claims, indications, symptoms treated, or dosage instructions.

Help-Seeking / Disease-Awareness Campaigns:

May discuss a medical condition, symptoms, and encourage patients to talk to their healthcare provider.

Strict Prohibition: Must NOT mention any specific brand name, product name, or manufacturer's proprietary molecule.

Critical Legal Rule: A Canadian advertisement that connects a specific prescription brand name with a therapeutic claim or medical condition directed to the general public is illegal under the Food and Drugs Act.

Controlled Drugs and Substances Act (CDSA): Structure & Schedules

Enacted in 1996, the Controlled Drugs and Substances Act (CDSA) repealed the former Narcotic Control Act and Parts III and IV of the Food and Drugs Act , consolidating Canada's control framework for substances with recognized potential for abuse, physical dependence, psychological addiction, or societal harm.

Legislative Purpose

The CDSA provides a dual-track framework: it establishes strict control mechanisms to enable the legitimate medical, scientific, and industrial use of scheduled substances while creating severe criminal law prohibitions against illicit manufacturing, importation, distribution, and diversion.

Overview of CDSA Schedules

CDSA Schedule Primary Drug Classes Included Key Representative Substances

Schedule I Opioids and related substances, coca, amphetamines and methamphetamine, and others Morphine, oxycodone, hydromorphone, fentanyl, methadone, tramadol, cocaine, heroin, ketamine, amphetamine, methamphetamine

Schedule II Synthetic cannabinoid receptor agonists (cannabis itself moved to the Cannabis Act in 2018) Synthetic cannabinoids

Schedule III Stimulants and hallucinogens not in Schedule I Methylphenidate, lysergic acid diethylamide (LSD), mescaline, psilocybin

Schedule IV Sedative-hypnotics, anxiolytics and anabolic steroids Benzodiazepines (lorazepam, diazepam), barbiturates, anabolic steroids (testosterone)

Schedule V Temporary listings: new psychoactive substances and precursors controlled for a limited period while permanent scheduling is considered Substances listed with a defined period

Schedule VI Precursors used in illicit drug production Class A: ephedrine, pseudoephedrine, red phosphorus; Class B: solvents such as acetone and toluene

Amphetamines and methamphetamine moved from Schedule III to Schedule I in 2012. The old cannabis sentencing Schedules VII and VIII were repealed when the Cannabis Act came into force.

Core Criminal Offenses under the CDSA

Section 4 (Unlawful Possession): Prohibits obtaining or possessing any substance in Schedules I, II, or III without lawful authorization (e.g., a valid prescription or Section 56 exemption).

Section 5 (Trafficking and Possession for the Purpose of Trafficking): Prohibits selling, administering, giving, transferring, transporting, or distributing a scheduled substance without authorization.

Section 6 (Importing and Exporting): Strictly forbids transporting controlled substances across international borders without an explicit federal permit.

Section 7 (Production): Prohibits manufacturing, synthesizing, or cultivating scheduled substances without a federal dealer's licence.

Health Canada Enforcement, Office of Controlled Substances & Loss/Theft Reporting

The Office of Controlled Substances (OCS) within Health Canada administers federal controlled substance regulations, issues Dealer's Licences to pharmaceutical manufacturers and wholesalers, conducts facility audits, and grants ministerial exemptions under Section 56 of the CDSA (such as authorizing Supervised Consumption Sites or specialized scientific research).

  • Mandatory Loss and Theft Reporting Discovery of Loss or Theft (technician notifies the pharmacist immediately)
  • │
  • ▼
  • Theft (break-in, robbery, forged Rx that was filled): report to police
  • │
  • ▼
  • Investigate and document (counts, records, possible explanation)
  • │
  • ▼
  • Pharmacist submits a written report to Health Canada
  • (E-Services Portal or Loss or Theft Report Form)
  • ⏰ WITHIN 10 DAYS AFTER BECOMING AWARE

Statutory Timeline: Under the CSR (s. 109) , a pharmacist who becomes aware of a loss or theft of a controlled substance, or is told about one by an agent or employee, must give the Minister of Health a written report within 10 days . The legacy rules had the same 10-day deadline (NCR s. 42, FDR G.03.013, BOTSR s. 72).

Technician Duty: A pharmacy technician who discovers a loss or theft must notify the pharmacist immediately .

Reporting Mechanism: Reports go through Health Canada's E-Services Portal or its Loss or Theft Report Form, following Health Canada's guidance document on reporting loss or theft of controlled substances (CS-GD-005).

Police: Thefts such as robberies and break-ins are reported to the police. Keep the police report details, because Health Canada's report asks about police involvement.

What Must Be Reported?

Theft: any removal without legitimate consent, including a forged prescription that was filled in whole or in part. An attempted forgery where nothing was dispensed is not reported to Health Canada.

Loss: a physical disappearance that cannot be explained when discovered (for example, an unexplained shortfall in a perpetual inventory count, or stock missing from a delivery).

Internal diversion discovered through audits or surveillance is a theft.

Explained Losses vs. Reportable Losses

Witnessed breakage or spillage: If an oxycodone tablet is dropped down a drain in front of a colleague, or a bottle of methadone solution breaks, the fate of the drug is known. Document it right away (what, how much, how, who witnessed it) and adjust the inventory record according to the pharmacy's procedures.

If the quantity cannot be reconciled or the explanation is doubtful, treat it as an unexplained loss and report it within 10 days.

Loading diagram... Canadian Federal Drug Regulatory Architecture under Health Canada